MRVAC

MRVAC is a live-attenuated combination vaccine developed for the prevention of measles and rubella. Produced by the Center for Research and Production of Vaccines and Biologicals (POLYVAC) in Vietnam, the vaccine was created using technology transferred from Japan (specifically from Kitasato Daiichi Sankyo Vaccine). It contains the AIK-C strain of the measles virus and the Takahashi strain of the rubella virus, both attenuated to induce a protective immune response without causing disease. Clinical trials, including a Phase III study in Vietnamese volunteers aged 1 to 45 years, have demonstrated that MRVAC is safe and provides immunogenicity non-inferior to established international vaccines like those from the Serum Institute of India. It is a key component of Vietnam's national expanded program on immunization, providing a locally manufactured option for disease control.

Brand names

MRVAC

Other names

Measles-Rubella combined vaccine